Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Executive Summary
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4